CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128.
Badawi M, Kim J, Dauki A, Sutaria D, Motiwala T, Reyes R, Wani N, Kolli S, Jiang J, Coss CC, Jacob ST, Phelps MA, Schmittgen TD.
Badawi M, et al. Among authors: motiwala t.
Oncotarget. 2018 May 25;9(40):26032-26045. doi: 10.18632/oncotarget.25430. eCollection 2018 May 25.
Oncotarget. 2018.
PMID: 29899840
Free PMC article.